Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00242554 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2017-02-23
Summary
To assess the effects of i.v. zoledronic acid 4 mg with respect to safety and tolerability
Conditions
Interventions
- DRUG
-
Zoledronic acid
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-10-31
- Primary Completion
- 2007-07-31
More Related Trials
-
Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00237146 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00334139 ·Status: COMPLETED ·Phase: PHASE4
-
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
NCT00005073 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
NCT00375648 ·Status: COMPLETED ·Phase: PHASE3
-
Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00219271 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
NCT00055471 ·Status: COMPLETED ·Phase: PHASE2
-
Maintaining Bone Strength in Men With Prostate Cancer
NCT00391950 ·Status: TERMINATED ·Phase: PHASE3
-
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
NCT00181584 ·Status: COMPLETED ·Phase: PHASE2
-
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
NCT00520052 ·Status: COMPLETED ·Phase: NA
-
A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer
NCT01000948 ·Status: TERMINATED ·Phase: PHASE2
-
Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00035997 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
NCT00172055 ·Status: COMPLETED ·Phase: PHASE3
-
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
NCT00171639 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
NCT00502164 ·Status: COMPLETED ·Phase: PHASE1
-
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
NCT00079001 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00063609 ·Status: COMPLETED ·Phase: PHASE4
-
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
NCT00087659 ·Status: COMPLETED ·Phase: NA
-
ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)
NCT00090363 ·Status: COMPLETED ·Phase: PHASE2
-
Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC
NCT01062503 ·Status: COMPLETED
-
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
NCT00459654 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP Trial
NCT00540059 ·Status: COMPLETED
-
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
NCT00004928 ·Status: COMPLETED ·Phase: PHASE1
-
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
NCT00489905 ·Status: COMPLETED ·Phase: NA
-
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
NCT00039104 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer
NCT03450109 ·Status: COMPLETED ·Phase: PHASE1